While modern approaches have demonstrated how metabolites are utilized in exquisite detail, recent studies suggest that the heterogeneous nature of the tumor microenvironment, the interconnected nature of cellular metabolism, and the plasticity of intracellular metabolic pathways create significant hurdles to successful application of targeting a single, highly specific glutamine metabolic pathway such as glutaminase activity. The gene discussed is GLS; the disease is neoplasm.